What is Novartis without Sandoz? Vas Narasimhan is 'patient' as new company takes form

Vas Narasimhan is steadfast on his mission to reshape Novartis, culling a few programs last quarter and making the final arrangements to spin off generics unit Sandoz. But make no mistake — he’s also “willing to be patient.”